RELMADA THERAPEUTICS, INC. current report, 27 October 2020

RELMADA THERAPEUTICS, INC. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Relmada Therapeutics, Inc. on October 27, 2020. The company is incorporated in Nevada and its common stock trades on The Nasdaq Global Select Market under the symbol "RLMD". The report addresses corporate governance updates rather than financial performance.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is not a financial statement and contains no quantitative financial data.

Material Changes

The material event reported is the appointment of two new officers, as detailed in the press release attached as Exhibit 99.1. No financial or operational changes were disclosed in this specific filing.

Guidance, Outlook, and Risks

The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The document strictly serves to disclose the personnel changes referenced in Item 8.01.

Investor Verification Checklist

  • Verify the names and specific titles of the two newly appointed officers in the attached press release (Exhibit 99.1).
  • Confirm the effective date of the appointments.
  • Review the company's most recent 10-Q or 10-K for current financial metrics, as this 8-K does not contain them.